Entera Bio (NASDAQ:ENTX) Trading Up 10.8% – What’s Next?

Entera Bio Ltd. (NASDAQ:ENTX)’s share price was up 10.8% during mid-day trading on Monday . The stock traded as high as $2.35 and last traded at $2.06. Approximately 4,272,735 shares were traded during mid-day trading, an increase of 10,648% from the average daily volume of 39,755 shares. The stock had previously closed at $1.86.

Entera Bio Stock Up 10.8%

The firm has a fifty day simple moving average of $1.95 and a 200-day simple moving average of $2.03. The company has a market capitalization of $93.63 million, a P/E ratio of -7.92 and a beta of 1.46.

Entera Bio (NASDAQ:ENTX) last announced its quarterly earnings results on Friday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. Entera Bio had a negative return on equity of 95.10% and a negative net margin of 4,525.11%. The company had revenue of $0.04 million during the quarter. On average, sell-side analysts predict that Entera Bio Ltd. will post -0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. HighTower Advisors LLC boosted its position in shares of Entera Bio by 53.3% during the first quarter. HighTower Advisors LLC now owns 18,140 shares of the company’s stock worth $31,000 after buying an additional 6,310 shares during the period. Northern Trust Corp acquired a new position in shares of Entera Bio during the fourth quarter worth about $450,000. Parkman Healthcare Partners LLC boosted its position in shares of Entera Bio by 6.3% during the first quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company’s stock worth $747,000 after buying an additional 25,900 shares during the period. Finally, Knoll Capital Management LLC boosted its position in shares of Entera Bio by 51.5% during the fourth quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company’s stock worth $12,470,000 after buying an additional 2,000,000 shares during the period. 14.11% of the stock is owned by institutional investors and hedge funds.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.